The Weight of Hepatotoxicity: Liver Injury in the Age of Weight Loss Therapies

The exponential global rise in type 2 diabetes, obesity, and metabolic dysfunction–associated steatohepatitis (MASH) has driven the pursuit of increasingly effective therapies. Glucagon-like peptide-1 receptor agonsits (GLP-1 RAs) have revolutionaled the management of these diseases but are not without risk. While rare, liver injury potentially associated with GLP-1 RA use is becoming more widely known; it is an increasing concern for drug developers as well as clinicians and their patients. Similarly, patients continue to search for and utilize herbs and supplements that purport to improve these metabolic conditions, some of which may have adverse effects on the liver. This interactive program focuses on GLP-1 RAs and herbal/supplemental remedies used for weight reduction and their potential adverse effects on the liver, sometimes severe.  A lively panel discussion follows speaker presentations.